Evidence map›Paper›PMID 34948878›Full record

Observational studyInternational journal of environmental research and public health2021

Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona.

Arantza Sanvisens, Montse Puigdemont, Jordi Rubió-Casadevall, Anna Vidal-Vila, Eugeni López-Bonet, Ferran Martín-Romero, Rafael Marcos-Gragera

Abstract readObservational Study
In one paragraph

Observational study in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arantza SanvisensEpidemiology Unit and Girona Cancer Registry, Institut de Recerca Contra la Leucèmia Josep Carreras, 17004 Girona, Spain.ORCID 0000-0001-6269-5491
Montse PuigdemontEpidemiology Unit and Girona Cancer Registry, Institut Català d'Oncologia, Pla Director d'Oncologia, 17004 Girona, Spain.ORCID 0000-0001-9961-3699
Jordi Rubió-CasadevallInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), 17004 Girona, Spain.
Anna Vidal-VilaEpidemiology Unit and Girona Cancer Registry, Institut Català d'Oncologia, Pla Director d'Oncologia, 17004 Girona, Spain.
Eugeni López-BonetDepartment of Pathology, Hospital Universitari Dr. Josep Trueta, 17007 Girona, Spain.
Ferran Martín-RomeroDepartment of Pathology, Hospital de Figueres, Fundació Salut Empordà, 17600 Figueres, Spain.
Rafael Marcos-GrageraEpidemiology Unit and Girona Cancer Registry, Institut de Recerca Contra la Leucèmia Josep Carreras, 17004 Girona, Spain.ORCID 0000-0001-9824-3657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe recent COVID-19 pandemic has compromised socio-health care, with consequences for the diagnosis and follow-up of other pathologies. The aim of this study was to evaluate the impact of COVID-19 on cancer diagnosis in Girona, Spain. METHODOLOGY: Observational study of samples received in two pathology laboratories during 2019-2020 (tertiary hospital in Girona and county hospital in Figueres). Date, sample type, and location and morphology were available. Samples were recoded to determine malignancy and grouped by location. Comparisons were made by calendar year and period of exposure to COVID-19.

results102,360 samples were included: 80,517 from Girona and 21,843 from Figueres. The reduction in activity in the pathology laboratories in 2020 compared to the previous year was 25.4% in Girona and 27.5% in Figueres. The reduction in cancer diagnoses in 2020 compared to 2019 was 6.8% in Girona and 21% in Figueres. In both laboratories, a decrease was observed in the diagnoses of neoplasms of the lip, oral cavity and pharynx, larynx, colon, rectum and anus, kidney and urinary system, melanoma, and central nervous system. A statistically significant higher probability of a sample received in the pathology laboratory displaying malignancy during COVID-19 was found (Girona: OR = 1.28, 95% CI: 1.23-1.34; Figueres: OR = 1.10, 95% CI: 1.01-1.20) with respect to the COVID-19-free period.

conclusionsThe COVID-19 pandemic has resulted in a reduction in cancer diagnoses by pathology departments that varies according to tumor location and type of hospital. Despite this, the optimization of care resources and the recovery effort have partially reduced the impact of the pandemic in certain neoplasms.

Indexed as

COVID-19MelanomaHumansLaboratoriesPandemicsSARS-CoV-2cancerCOVID-19diagnosispathology

Identifiers

PMID34948878
PMCPMC8701849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.